- Home
- JYNT vs ENGN Comparison
JYNT vs ENGN Comparison
Compare JYNT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYNT
- ENGN
- Stock Information
- Founded
- JYNT 2010
- ENGN 1999
- Country
- JYNT United States
- ENGN Canada
- Employees
- JYNT N/A
- ENGN N/A
- Industry
- JYNT Multi-Sector Companies
- ENGN
- Sector
- JYNT Miscellaneous
- ENGN
- Exchange
- JYNT Nasdaq
- ENGN Nasdaq
- Market Cap
- JYNT 170.1M
- ENGN 191.1M
- IPO Year
- JYNT 2014
- ENGN N/A
- Fundamental
- Price
- JYNT $11.60
- ENGN $3.37
- Analyst Decision
- JYNT Strong Buy
- ENGN Buy
- Analyst Count
- JYNT 2
- ENGN 7
- Target Price
- JYNT $15.50
- ENGN $23.29
- AVG Volume (30 Days)
- JYNT 73.1K
- ENGN 84.5K
- Earning Date
- JYNT 08-07-2025
- ENGN 09-09-2025
- Dividend Yield
- JYNT N/A
- ENGN N/A
- EPS Growth
- JYNT N/A
- ENGN N/A
- EPS
- JYNT N/A
- ENGN N/A
- Revenue
- JYNT $52,789,479.00
- ENGN N/A
- Revenue This Year
- JYNT $9.48
- ENGN N/A
- Revenue Next Year
- JYNT $11.15
- ENGN N/A
- P/E Ratio
- JYNT N/A
- ENGN N/A
- Revenue Growth
- JYNT 71.05
- ENGN N/A
- 52 Week Low
- JYNT $9.58
- ENGN $2.65
- 52 Week High
- JYNT $15.32
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- JYNT 54.97
- ENGN 40.69
- Support Level
- JYNT $11.71
- ENGN $2.95
- Resistance Level
- JYNT $12.27
- ENGN $3.98
- Average True Range (ATR)
- JYNT 0.62
- ENGN 0.27
- MACD
- JYNT -0.01
- ENGN 0.02
- Stochastic Oscillator
- JYNT 46.05
- ENGN 34.29
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.